[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356314-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356314-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","challenging-the-extended-phenotype-hrd-negative-salivary-gland-carcinoma-in-a-brca1-founder-variant-carrier-case-report-and-literature-review","Challenging the extended phenotype - HRD-negative salivary gland carcinoma in a BRCA1 founder-variant carrier - case report and literature review","","Pathogenic BRCA1 variants are established drivers of hereditary breast and ovarian cancer (HBOC) and are also linked to additional malignancies, while salivary gland tumors (SGTs) have been proposed as part of an extended HBOC phenotype. This case report and literature review evaluates HRD status in a BRCA1 founder-variant carrier with mucoepidermoid carcinoma of the parotid gland, finding preserved homologous recombination function and no BRCA1 loss of heterozygosity. The absence of HRD challenges causal assumptions and informs clinical testing and management, including PARP inhibitor eligibility.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/challenging-the-extended-phenotype-hrd-negative-salivary-gland-carcinoma-in-a-brca1-founder-variant-carrier-case-report-and-literature-review/356314/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/challenging-the-extended-phenotype-hrd-negative-salivary-gland-carcinoma-in-a-brca1-founder-variant-carrier-case-report-and-literature-review/356314.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical and genetic features were identified in the reported BRCA1 carrier case?","Question",{"text":63,"@type":64},"A 61-year-old woman developed high-grade mucoepidermoid carcinoma of the parotid gland. Germline testing confirmed the familial BRCA1 founder variant, and tumor profiling detected the same BRCA1 variant plus a pathogenic TP53 mutation without BRCA1 loss of heterozygosity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was HRD assessed, and what were the main results?",{"text":68,"@type":64},"HRD was evaluated using shallow whole genome sequencing. Homologous recombination function was preserved with a Genomic Instability Score of 0.01, LGA of 11.40, and LPC of 0, all below HRD-positive thresholds.",{"name":70,"@type":61,"acceptedAnswer":71},"Why do the findings challenge the presumed role of BRCA1 variants in salivary gland tumor development?",{"text":72,"@type":64},"Although the BRCA1 variant segregated across generations and was present in the tumor, the tumor showed no HRD. This argues against BRCA1-driven tumorigenesis in this case and suggests that co-occurrence alone does not establish causation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356314,1790160433,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","TYPE Case Report  \nPUBLISHED 21 January 2026 DOI 10.3389/fonc.2025.1692001  \nOPEN ACCESS  \nEDITED BY  \nPaolo Radice,  \nNational Cancer Institute Foundation (IRCCS), Italy  \nREVIEWED BY  \nPaolo Aretini,  \nFondazione Pisana per la Scienza Onlus, Italy Danendra Rakha Putra Respati,  \nDiponegoro University, Indonesia  \n*CORRESPONDENCE  \nJulian C Riaño-Moreno  \n[jcriano@cancer.gov.co](jcriano@cancer.gov.co)[ ](jcriano@cancer.gov.co)William Torres  \n [wtorres@cancer.gov.co](wtorres@cancer.gov.co)  \nRECEIVED 25 August 2025  \nREVISED 27 December 2025  \nACCEPTED 30 December 2025  \nPUBLISHED 21 January 2026  \nCITATION  \nTorres W, Vargas E, Ballen D-F, TapieroRodriguez SM, Cadena E, Parra-Medina R and Riaño-Moreno JC (2026) Challenging the extended phenotype: HRD-negative salivary gland carcinoma in a BRCA1 founder-variant carrier, case report and literature review. Front. Oncol. 15:1692001 .  \ndoi: 10.3389/fonc.2025.1692001  \nCOPYRIGHT  \n© 2026 Torres, Vargas, Ballen, TapieroRodriguez, Cadena, Parra-Medina and RiañoMoreno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nChallenging the extended phenotype: HRD-negative salivary gland carcinoma in a BRCA1 founder-variant carrier, case report and literature review  \nWilliam Torres 1*, Elizabeth Vargas 2, Diego-Felipe Ballen 3, Sandra M Tapiero-Rodriguez 1, Enrique Cadena 4, Rafael ParraMedina 1 and Julian C Riaño-Moreno 1,5*  \n1 Department of Pathology and Molecular Oncology, Instituto Nacional de Cancerologa, Bogot´a,  \nD.C, Colombia, 2Career Researcher, Hospital Universitario Mayor-Me´deri, Universidad del Rosario, Bogot´a, D.C, Colombia, 3Clinical Oncology Unit, Instituto Nacional de Cancerologa, Bogot´a, D.C, Colombia,  \n4 Head and Neck Surgery Unit, Instituto Nacional de Cancerologa, Bogot´a, D. C, Colombia, 5 Faculty of Medicine, Universidad Cooperativa de Colombia, Villavicencio, Colombia  \nBackground: Pathogenic BRCA1 variants are established in hereditary breast and ovarian cancer (HBOC) and associated with pancreatic, prostate, and gastric cancers. Salivary gland tumors (SGTs) have been reported in BRCA1/2 carriersand suggested as part of an extended HBOC phenotype based on epidemiological associations. However, functional evidence is lacking, and homologous recombination deﬁciency (HRD)—the hallmark of BRCA-driven cancers—has not been systematically assessed in BRCA1-associated SGTs.  \nCase presentation: We report a Colombian family segregating the BRCA1 c.3331_3334delCAAG (p.Gln1111Asnfs*5) founder variant with phenotypic variability across four generations: gastric (31%), breast (37.5%), colorectal (19%), and thyroid cancers (12 . 5%) . The proband, a 61-year-old woman, developed high-grade mucoepidermoid carcinoma of the parotid gland. Germline testing conﬁrmed the familial BRCA1 variant. Tumor proﬁling revealed the same BRCA1 variant (VAF 56%) plus a pathogenic TP53 mutation (c.730G>T, p. Gly244Cys; VAF 32%), without BRCA1 loss of heterozygosity. HRD testing using shallow whole genome sequencing showed preserved homologous recombination function (Genomic Instability Score: 0.01, LGA: 11.40, LPC: 0), all below HRD-positive thresholds.  \nConclusion: This represents the ﬁrst SGT in a BRCA1 carrier evaluated with HRD testing. The absence of HRD argues against BRCA1-driven tumorigenesis despite clear familial segregation. These ﬁndings challenge the presumed causal relationship between BRCA1 variants and SGT development. Clinical implications are direct: SGTs in BRCA1 carriers should not be assumed eligible  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nfor PARP inhi","cbCairDtkvpz5W3q","https://ap.wps.com/l/cbCairDtkvpz5W3q","pdf",1634561,"English","# Background\n# Case presentation\n# Conclusion\n# Introduction","[{\"question\":\"What clinical and genetic features were identified in the reported BRCA1 carrier case?\",\"answer\":\"A 61-year-old woman developed high-grade mucoepidermoid carcinoma of the parotid gland. Germline testing confirmed the familial BRCA1 founder variant, and tumor profiling detected the same BRCA1 variant plus a pathogenic TP53 mutation without BRCA1 loss of heterozygosity.\"},{\"question\":\"How was HRD assessed, and what were the main results?\",\"answer\":\"HRD was evaluated using shallow whole genome sequencing. Homologous recombination function was preserved with a Genomic Instability Score of 0.01, LGA of 11.40, and LPC of 0, all below HRD-positive thresholds.\"},{\"question\":\"Why do the findings challenge the presumed role of BRCA1 variants in salivary gland tumor development?\",\"answer\":\"Although the BRCA1 variant segregated across generations and was present in the tumor, the tumor showed no HRD. This argues against BRCA1-driven tumorigenesis in this case and suggests that co-occurrence alone does not establish causation.\"}]","Challenging the extended phenotype - HRD-negative salivary gland carcinoma in a BRCA1 founder-variant carrier - case report and literature review | PDF",1790124619,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3523413b774851c6fc889d458bcfd0c2.webp",983,1389,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe636b14f796bbcb1e0017cb63a25dad.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/890e37a88785372aada3e7569f0a0b95.webp",981,1386,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3147e61299b2c0230990370c8e5d6f8.webp",980,1385]